Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Life sciences executive brings more than 25 years of experience
to cell and gene therapy company progressing through pivotal Phase 3 clinical trial